Concordance between substance P levels and antiemetic guidelines

Journal of Supportive Oncology

Volumn 7, Issue 4, 2009, Pages 138-142

  Higa, Gerald M ^a   Auber, Miklos L ^a   Altaha, Ramin ^a   Kurian, Sohba ^a   Hobbs, Gerry ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; APREPITANT; CISPLATIN; DEXAMETHASONE; DOLASETRON MESILATE; NEUROKININ 1 RECEPTOR ANTAGONIST; SUBSTANCE P;

ANTIEMETIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL RESEARCH; DRUG EFFICACY; DRUG SAFETY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRACTICE GUIDELINE; PROTEIN BLOOD LEVEL; STANDARD; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; SUBSTANCE P; VOMITING;

EID: 70349245274     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Diemunsch P, Grélot L. Potential of substance P antagonists as antiemetics. Drugs 2000;60:535-546.
2. Heitz P, Polak JM, Timson DM, Pearse AG. Enterochromaffin cells as the endocrine source of gastrointestinal substance P. Histochemistry 1976;49:343-347.
3. Andrews PL, Bhandari P. Resinferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret. Neuropharmacology 1993;32:799-806.
4. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-4119.
5. 1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003;97:2290-2300.
6. Van Belle S, Lichinitser MR, Navari RM, et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 2002;94:3032-3041.
7. Campos D, Pereira JR, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001;19:1759-1767.
8. Navari RM, Reinhardt RR, Gralla RJ, et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N engl J Med 1999;340:190-195.
9. Higa GM, Auber ML, Altaha R, et al. 5-Hydroxy-indoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy. J Oncol Pharm Pract 2006;12:201-209.
10. Uemura M, Tsujii T, Kikuchi E, et al. Increased plasma levels of substance P and disturbed water excretion in patients with liver cirrhosis. Scand J Gastroenterol 1998;33:860-866.
11. Kris MG, Hesketh PJ, Herrstedt J, et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 2005;13:85-96.
12. American Society of Clinical Oncology, Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-2947.
13. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, v.2.2009: Antiemesis. www.nccn.org/professionals/ physician_gls/PDF/antiemesis.pdf. Accessed July 9, 2009.
14. Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 1997;53:983-997.
15. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-109.
16. Yanaihara C, Sato H, Hirohashi M, Sakagami M, Yamamoto K. Substance P radioimmunoassay using Nalpha-tyrosyl-substance P and demonstration of the presence of substance P-like immunoreactivities in human blood and porcine tissue extracts. Endocrinol Jpn 1976;23:457-463.
17. Cubeddu LX, O'Connor DT, Parmer RJ. Plasma chromogranin A: a marker of serotonin release and of emesis associated with cisplatin chemotherapy. J Clin Oncol 1995;13:681-687.